Company intelligence / Profile preview

Shanghai Yuansong Biotechnology Co., Ltd.

Shanghai, Shanghai Shi, Chinanature.com ↗

Ownership: Private
Development stage: Phase 2

Overview

YSCH‑01 has demonstrated safety and preliminary efficacy in a Phase I investigator‑initiated trial for advanced solid tumors. The product uses a genetically modified oncolytic adenovirus to deliver therapeutic genes selectively to tumor cells. Early results show the approach was well tolerated with signs of antitumor activity in heavily pretreated patients.[6] Additional programs are at preclinical or early clinical stages.[3]

Therapeutic areas: Oncology
Modalities: Oncolytic viruses (notably recombinant L-IFN adenovirus)
Industry: Biotech

Drug pipeline

2 assets

recombinant L-IFN adenovirus

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships publicly disclosed.

Beyond the preview

Go deeper on Shanghai Yuansong Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Yuansong Biotechnology Co., Ltd..

Explore the full profile